Category: ASX Release

Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM. The recent identification of Bisantrene as a potent inhibitor of the Fat and obesity associated (FTO) protein, together with the…

10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…

5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba…

Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will be responsible for progressing Race’s clinical development plans for Bisantrene.…

Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an inhibitor of the Fat mass and obesity-associated protein (FTO). Recent…

Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as regards progress in reframing the opportunity for Bisantrene in Acute…

The Board of Directors of Race Oncology wishes to advise that Dr. Peter Molloy has decided to step down as Managing Director and Chief Executive Officer. Chairman Dr John Cullity, and Chief Scientific Officer Dr Daniel Tillett will step into…

 Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. • Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00) • Race’s 5 Path Strategy | Dr Daniel Tillett CSO (10.00 – 39.00) • Conclusion…

17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd. Dr Daniel Tillett is the founder…